Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effectiveness of Third Occipital Nerve Pulsed Radiofrequency in Cervicogenic Headache

NCT07366060 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-02-01
Last updated
2026-01-26

Condition(s) studied

Cervicogenic HeadacheThird Occipital Nerve

Investigational drug(s) / intervention(s)

Third Occipital Nerve Pulsed Radiofrequency

Third Occipital Nerve Pulsed Radiofrequency: Ultrasound-guided pulsed radiofrequency treatment applied to the third occipital nerve at the C2-3 zygapophyseal joint level for the management of cervicogenic headache.

Study summary

Cervicogenic headache is a secondary headache disorder originating from cervical spine structures and is frequently associated with chronic pain, functional limitation, and impaired quality of life. The third occipital nerve, which innervates the C2-3 zygapophyseal joint, plays an important role in the pathophysiology of cervicogenic headache.

Pulsed radiofrequency is a minimally invasive interventional pain management technique that modulates nociceptive transmission without causing permanent neural damage. Although third occipital nerve pulsed radiofrequency is increasingly used in clinical practice, prospective data evaluating its clinical effectiveness and safety remain limited.

The aim of this prospective, single-center study is to evaluate the effectiveness and safety of ultrasound-guided third occipital nerve pulsed radiofrequency treatment in patients diagnosed with cervicogenic headache. Pain intensity, headache characteristics, analgesic consumption, and patient-reported outcomes will be assessed before treatment and during follow-up. The results of this study are expected to contribute to clinical evidence supporting interventional treatment strategies for cervicogenic headache.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 18 years or older * Diagnosis of cervicogenic headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) * Availability of cranial and cervical spine imaging * At least 5 headache days per month * Inadequate response to pharmacological and/or physical therapy treatments * Ability to understand and provide written informed consent * Positive response to ultrasound-guided diagnostic third occipital nerve block, defined as at least 50% reduction in pain intensity or patient-reported meaningful improvement Exclusion Criteria: * Secondary headache disorders other than cervicogenic headache according to ICHD-3 * Signs or symptoms of cervical nerve root irritation and/or spinal stenosis * Sensory deficit in the greater occipital nerve dermatome * Cranio-cervical structural defects or anatomical abnormalities at or near the target site * Local or systemic infection * Non-pharmacological headache treatment within the last 3 months (e.g., physical therapy, botulinum toxin A, acupuncture, ozone therapy, cognitive behavioral therapy) * Pregnancy or suspected pregnancy * Known allergy to local anesthetic agents * History of malignancy * Known organic disease of the brain or spinal cord * History of cranial or cervical surgery within the last 12 months * Bleeding or coagulation disorders or use of oral anticoagulant therapy * Comorbid conditions that may cause headache (e.g., uncontrolled hypertension, intracranial lesions) * Conditions that may interfere with treatment adherence or outcome assessment (e.g., psychiatric disorders, dementia) * Request for re-treatment due to development of contralateral pain or other pain conditions during follow-up * Refusal to undergo the intervention or withdrawal of consent at any stage of the study

Primary outcome measure(s)

  • Change in pain intensity measured by Visual Analog Scale (VAS) — Baseline, and 1, 2, and 3 months after the procedure
    Pain intensity will be assessed using the Visual Analog Scale (VAS) to evaluate changes in headache-related pain following third occipital nerve pulsed radiofrequency treatment.

Trial sites (1)

FacilityCityRegionStatus
Ankara City Hospital Bilkent Ankara Ankara Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07366060 on ClinicalTrials.gov ↗ ← All trials in Turkey